Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and <i>TP53</i> -Mutant Tumors and Identifies <i>NRAS</i> as an Oncogenic Driver

Abstract

Our findings suggest that NRAS is an oncogenic driver in serous ovarian tumors. We demonstrate that borderline histology is an unreliable predictor of Ras pathway aberration and underscore an important role for molecular classification in identifying patients that may benefit from targeted agents.